The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.
Carlos Zamora AtenzaGeòrgia AngueraMariona Riudavets MeliàLetícia Alserawan De LamoIvana SullivanAndrés Barba JoaquinJorgina Serra LopezM Angels OrtizMaria MuletSílvia VidalMargarita Majem TarruellaPublished in: Cancer immunology, immunotherapy : CII (2022)
Our results suggest that integrating circulating PD-L1 + leukocytes, PLT, PMPs, and sPD-L1 and tumor PD-L1 expression may be helpful to decide on the best treatment strategy in patients with advanced NSCLC who are candidates for PD-(L)1 blockade agents.